In a preclinical study using an animal model of myocardial ischemia/reperfusion (I/R) injury, semaglutide increased GLP-1R expression, activating the PKG/PKCε/ERK1/2 (protein kinase G/protein kinase C epsilon/extracellular signal-regulated kinase 1/2 pathway, which inhibited cardiomyocyte apoptosis. The gene discussed is MAPK3; the disease is myocardial ischemia.